CA2784304A1 - Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique - Google Patents

Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique Download PDF

Info

Publication number
CA2784304A1
CA2784304A1 CA2784304A CA2784304A CA2784304A1 CA 2784304 A1 CA2784304 A1 CA 2784304A1 CA 2784304 A CA2784304 A CA 2784304A CA 2784304 A CA2784304 A CA 2784304A CA 2784304 A1 CA2784304 A1 CA 2784304A1
Authority
CA
Canada
Prior art keywords
pain
compound according
composition
chronic pain
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2784304A
Other languages
English (en)
Inventor
Benny Bang-Andersen
Andre Faldt
Tine Bryan Stensbol
Silke Miller
Heidi Lopez De Diego
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority claimed from CA2656057A external-priority patent/CA2656057C/fr
Publication of CA2784304A1 publication Critical patent/CA2784304A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/12—Glutaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CA2784304A 2006-06-16 2007-06-15 Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique Abandoned CA2784304A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80500906P 2006-06-16 2006-06-16
DKPA200600816 2006-06-16
US60/805,009 2006-06-16
DKPA20060816 2006-06-16
DKPA200700423 2007-03-20
DKPA200700423 2007-03-20
CA2656057A CA2656057C (fr) 2006-06-16 2007-06-15 Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2656057A Division CA2656057C (fr) 2006-06-16 2007-06-15 Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique

Publications (1)

Publication Number Publication Date
CA2784304A1 true CA2784304A1 (fr) 2007-12-21

Family

ID=39722478

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784304A Abandoned CA2784304A1 (fr) 2006-06-16 2007-06-15 Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique

Country Status (15)

Country Link
JP (1) JP2014098017A (fr)
KR (1) KR101472595B1 (fr)
AR (1) AR061480A1 (fr)
AT (1) ATE508115T1 (fr)
BR (1) BRPI0712758A2 (fr)
CA (1) CA2784304A1 (fr)
DE (1) DE602007014372D1 (fr)
DK (1) DK2044020T3 (fr)
MY (1) MY150698A (fr)
NZ (1) NZ572856A (fr)
PT (1) PT2044020E (fr)
RS (1) RS51687B (fr)
SI (1) SI2044020T1 (fr)
TN (1) TNSN08461A1 (fr)
TW (1) TWI444365B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116930385A (zh) * 2023-08-08 2023-10-24 北京爱思益普生物科技股份有限公司 一种高盐浓度制剂中化合物浓度的测定方法
CN117305360A (zh) * 2023-09-15 2023-12-29 江南大学 一种哺乳动物细胞核转染液及其制备方法和在细胞核内递送的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972931B1 (ko) 2017-10-19 2019-04-26 재단법인대구경북과학기술원 풍선 타입 피질전도 측정장치 및 이의 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116930385A (zh) * 2023-08-08 2023-10-24 北京爱思益普生物科技股份有限公司 一种高盐浓度制剂中化合物浓度的测定方法
CN116930385B (zh) * 2023-08-08 2024-02-20 北京爱思益普生物科技股份有限公司 一种高盐浓度制剂中化合物浓度的测定方法
CN117305360A (zh) * 2023-09-15 2023-12-29 江南大学 一种哺乳动物细胞核转染液及其制备方法和在细胞核内递送的应用

Also Published As

Publication number Publication date
AR061480A1 (es) 2008-08-27
TWI444365B (zh) 2014-07-11
BRPI0712758A2 (pt) 2012-09-25
RS51687B (en) 2011-10-31
TNSN08461A1 (en) 2010-04-14
PT2044020E (pt) 2011-05-12
ATE508115T1 (de) 2011-05-15
JP2014098017A (ja) 2014-05-29
TW200817329A (en) 2008-04-16
SI2044020T1 (sl) 2011-06-30
DK2044020T3 (da) 2011-08-15
KR101472595B1 (ko) 2014-12-15
KR20090018630A (ko) 2009-02-20
MY150698A (en) 2014-02-28
NZ572856A (en) 2012-02-24
DE602007014372D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
CA2656057C (fr) Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
AU2008228639B2 (en) 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
US20170087138A1 (en) Therapeutic Uses Of Compounds Having Affinity To The Serotonin Transporter, Serotonin Receptors And Noradrenalin Transporter
CA2784304A1 (fr) Formes cristallines de la 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine avec inhibition de la reabsorption de la serotonine et de la norepinephrine en combinaison pour le traitement de la douleur neuropathique
ES2361949T3 (es) Formas cristalinas de 4-[2-(4-metilfenilsulfanil)-fenil]piperidina con inhibición de la reabsorción de serotonina y norepinefrina combinada para el tratamiento del dolor neuropático.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150903